CagriSema

New to peptides? Start with what are peptides? and how do peptides work?

Overview

CagriSema is not a new molecule. It is a fixed-dose combination of two peptides that already exist separately: semaglutide, the GLP-1 receptor agonist sold as Ozempic and Wegovy, and cagrilintide, a long-acting analog of the satiety hormone amylin. Novo Nordisk put them in a single once-weekly injection on the theory that engaging two independent appetite systems would produce more weight loss than engaging either alone.

Why the combination approach matters

Obesity pharmacology has spent the last few years asking what comes after GLP-1. One answer has been to add more receptors to a single molecule, which is what tirzepatide (GLP-1 plus GIP) and retatrutide (GLP-1 plus GIP plus glucagon) do. The other answer is to combine separate drugs that work through separate hormone systems. CagriSema is the flagship of that second strategy, and amylin is widely considered the most promising partner pathway.

Regulatory status

Novo Nordisk submitted a New Drug Application to the FDA in December 2025. As of August 2026 CagriSema is not approved, and a decision is anticipated later in 2026. Nothing sold under the name CagriSema outside a clinical trial is a legitimate product — there is no approved supply, and unapproved copies carry the usual risks of unverified identity, purity, and sterility.

How it works

Two appetite systems, one injection

The two components act on different receptors in different places, which is the whole point of the design.

• Semaglutide activates GLP-1 receptors. It slows gastric emptying, enhances glucose-dependent insulin secretion, suppresses glucagon, and acts on appetite centers in the hypothalamus and brainstem to reduce hunger and food intake.
• Cagrilintide activates amylin and calcitonin receptors. Amylin is co-secreted with insulin from pancreatic beta cells and signals meal-related fullness through the area postrema in the brainstem — anatomically and pharmacologically distinct from GLP-1 signaling.

The rationale for combining them

Because the pathways are separate, their effects should add rather than overlap, and each can be dosed at a level that is tolerable on its own. There is also a leptin-sensitivity argument: amylin analogs have been shown in preclinical work to restore some responsiveness to leptin, the hormone that signals long-term energy stores and whose signaling becomes blunted in obesity. If that translates to humans, an amylin analog might address a different part of the weight-regulation problem than incretin drugs do.

Cagrilintide by itself

Cagrilintide is engineered for once-weekly dosing, solving a practical problem that limited the earlier amylin analog pramlintide, which required injections with every meal. That formulation advance is what made a combination product feasible at all.

Clinical evidence

REDEFINE 1 — the headline result

In this Phase 3 trial in adults with overweight or obesity and without type 2 diabetes, CagriSema produced approximately 22.7% mean weight loss at 68 weeks. In the same trial semaglutide alone produced roughly 16.1% and cagrilintide alone considerably less, which supports the additive premise — the combination outperformed either component tested under identical conditions.

REDEFINE 2 — in type 2 diabetes

In adults with type 2 diabetes, CagriSema produced substantial weight loss alongside improved glycemic control. Weight loss in people with type 2 diabetes is consistently smaller than in people without it across this entire drug class, and CagriSema followed that pattern.

REDEFINE 4 — the head-to-head, and the miss

This is the result that reframed expectations, and it deserves to be reported plainly. REDEFINE 4 was an 84-week open-label trial in 809 adults with obesity that compared CagriSema directly against tirzepatide (Zepbound). CagriSema achieved about 23.0% weight loss versus about 25.5% for tirzepatide, and did not meet its primary endpoint of non-inferiority. Under the more conservative treatment-regimen analysis the figures were roughly 20.2% versus 23.6%.

Two things follow, and both are true at once. CagriSema produces large weight loss by any historical standard. And in the only direct comparison run so far, it did not match the existing market leader. A drug can be genuinely effective and still lose a head-to-head, and readers deciding what to make of the coverage deserve both halves of that sentence.

What is still unknown

Long-term cardiovascular outcome data for the combination are not yet available, nor are data on what happens to weight after stopping — though experience with the class suggests regain is likely without continued treatment. Regulatory review is ongoing.

Safety & status

Side effects

The adverse-effect profile is dominated by gastrointestinal symptoms — nausea, vomiting, diarrhea, and constipation — which is expected given that both components slow gastric emptying and act on nausea-related brainstem circuitry. In trials these were mostly mild to moderate and diminished over time, and dose escalation is used to limit them.

The class considerations that apply to GLP-1 drugs apply here too: pancreatitis and gallbladder disease have been reported with GLP-1 therapies, thyroid C-cell tumor warnings appear on GLP-1 labeling based on rodent data, and rapid weight loss of this magnitude raises questions about lean-mass preservation that the field is still working through. Cagrilintide contributes its own gastrointestinal burden.

Status and what it means practically

CagriSema is investigational and not FDA-approved as of August 2026. It is not available by prescription, and it is not available legitimately in any other form. Compounded or grey-market products claiming to be CagriSema are not the studied drug: the trial results above apply to a specific fixed-dose formulation manufactured to pharmaceutical standards, and none of that transfers to an unverified vial.

For context on the components, see our guides to semaglutide and cagrilintide; for the drug that beat it head-to-head, see tirzepatide.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025. Peer-reviewed study
2. Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025. Peer-reviewed study
3. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide with once-weekly semaglutide in type 2 diabetes: a phase 2 trial. Lancet. 2023. Peer-reviewed study
4. Garvey WT, Blüher M, Osorto Contreras CK, et al.. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025. Peer-reviewed study
5. Davies MJ, Bajaj HS, Broholm C, et al.. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025. Peer-reviewed study
6. Frias JP, Deenadayalan S, Erichsen L, et al.. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023. Peer-reviewed study
7. Enebo LB, Berthelsen KK, Kankam M, et al.. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021. Peer-reviewed study
8. Buse JB, Bajaj HS, Dalskov SM, et al.. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes Endocrinol. 2026. Peer-reviewed study